Optimizing Genomic Control in Hit Network-Target Set Model Associations with Lung Adenocarcinoma

Bo Wang1, Qiong Liu1,2, Yanda Li1,3

  • 1Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Dongzhimen, Beijing 100700, China.

Journal of Cancer
|January 6, 2023
PubMed

Insights

This study introduces an optimized hit network-target set (OHNS) for lung adenocarcinoma, improving cancer network analysis and drug development. The OHNS enhances understanding of disease progression and identifies potential new drug targets.

Area of Science:

  • Computational Biology
  • Network Medicine
  • Oncology

Background:

  • Hit network-target sets (HNSs) are crucial in cancer development but challenging to select due to complex node interactions and data limitations.
  • Existing methods struggle with node heterogeneity and incomplete node-hit information, complicating target identification.

Purpose of the Study:

  • To develop an optimized hit network-target set (OHNS) for lung adenocarcinoma by integrating various network components.
  • To evaluate the performance of different HNSs based on network structure, control capability, and clinical relevance.

Main Methods:

  • Constructed a lung adenocarcinoma regulatory network using TCGA data.
  • Derived driver nodes (DNs), core modules (CMs), and core nodes (CNs) using three distinct methods.
  • Integrated CMs, CNs, and DNs to form the OHNS and assessed its properties.

Main Results:

  • The OHNS demonstrates superior network centrality and control capabilities compared to other HNSs.
  • Identified three unique pathways within the OHNS, consistent with prior experimental findings.
  • Predicted 13 genes involved in lung adenocarcinoma prognosis and progression, with 12 showing potential as drug candidates or biomarkers.

Conclusions:

  • The OHNS provides a more effective framework for understanding and controlling cancer networks, aiding in predicting disease trends.
  • Facilitates the design of multi-target drugs and guides therapeutic strategies for lung adenocarcinoma.
  • Highlights 12 potential new drug and biomarker candidates for lung adenocarcinoma treatment.